← back to search

Marc Ferrante

Universitair Ziekenhuis Leuven ·
Area of research
Genetics · Epidemiology
Research interest
Research interests include Inflammatory Bowel Disease, Microscopic Colitis, Immunodeficiency and Autoimmune Disorders, and Biosimilars and Bioanalytical Methods.
h-index
81
citations
33,691
works
1,018
NIH funding
primary concept
Medicine
email

Recent publications

Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Clinical Gastroenterology and Hepatology 2025cited by 11position: middledoi
Extended Risankizumab Treatment in Patients With Crohn’s Disease Who Did Not Achieve Clinical Response to Induction Treatment
Clinical Gastroenterology and Hepatology 2025cited by 5position: middledoi
Risankizumab for Ulcerative Colitis
JAMA 2024cited by 106position: middledoi
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
The Lancet 2024cited by 87position: firstdoi
Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn’s Disease: A Belgian Multicentric Cohort Study
Inflammatory Bowel Diseases 2024cited by 32position: lastdoi
Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme
Journal of Crohn s and Colitis 2024cited by 16position: middledoi
OP06 Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study
Journal of Crohn s and Colitis 2024cited by 16position: middledoi
Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn’s Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies
Journal of Crohn s and Colitis 2024cited by 4position: middledoi
Vedolizumab for the Treatment of Chronic Pouchitis
New England Journal of Medicine 2023cited by 108position: middledoi
High Acetate Concentration Protects Intestinal Barrier and Exerts Anti-Inflammatory Effects in Organoid-Derived Epithelial Monolayer Cultures from Patients with Ulcerative Colitis
International Journal of Molecular Sciences 2023cited by 94position: middledoi
Dysbiosis and Associated Stool Features Improve Prediction of Response to Biological Therapy in Inflammatory Bowel Disease
Gastroenterology 2023cited by 76position: middledoi
Results of the Eighth Scientific Workshop of ECCO: Prevention and Treatment of Postoperative Recurrence in Patients With Crohn’s Disease Undergoing an Ileocolonic Resection With Ileocolonic Anastomosis
Journal of Crohn s and Colitis 2023cited by 39position: firstdoi
Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis
˜The œLancet. Gastroenterology & hepatology 2023cited by 36position: middledoi
SCFAs switch stem cell fate through HDAC inhibition to improve barrier integrity in 3D intestinal organoids from patients with obesity
iScience 2023cited by 33position: middledoi
Results of the Eighth Scientific Workshop of ECCO: Diagnosing Postoperative Recurrence of Crohn’s Disease After an Ileocolonic Resection With Ileocolonic Anastomosis
Journal of Crohn s and Colitis 2023cited by 28position: lastdoi
A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases
Journal of Crohn s and Colitis 2023cited by 25position: middledoi
Defining Comprehensive Disease Control for Use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations
Journal of Crohn s and Colitis 2023cited by 25position: middledoi
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn’s Disease in a Randomized Phase 3 Trial
Journal of Crohn s and Colitis 2023cited by 14position: firstdoi
S1 Risankizumab Versus Ustekinumab in Patients With Moderate to Severe Crohn’s Disease: Results From the Phase 3B SEQUENCE Trial
The American Journal of Gastroenterology 2023cited by 12position: middledoi
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
The Lancet 2022cited by 375position: lastdoi
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
The Lancet 2022cited by 307position: firstdoi
European Crohn’s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation
Journal of Crohn s and Colitis 2022cited by 271position: middledoi
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results
Gastroenterology 2022cited by 83position: middledoi
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results
Gastroenterology 2022cited by 72position: middledoi
INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn’s Disease Treated in the ADMIRE-CD Trial
Inflammatory Bowel Diseases 2022cited by 57position: middledoi
Effect of 5-Hydroxytryptophan on Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Controlled Trial
Gastroenterology 2022cited by 41position: middledoi
Comparison of the Risk of Crohn’s Disease Postoperative Recurrence Between Modified Rutgeerts Score i2a and i2b Categories: An Individual Patient Data Meta-analysis
Journal of Crohn s and Colitis 2022cited by 32position: middledoi
The impact of inflammation on the expression of drug transporters and metabolic enzymes in colonic tissue from ulcerative colitis patients
International Journal of Pharmaceutics 2022cited by 19position: middledoi
Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease
Inflammatory Bowel Diseases 2021cited by 78position: middledoi
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational study
United European Gastroenterology Journal 2021cited by 70position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Séverine Vermeire · Europe Hospitals90 papers (2013–2025)Gert Van Assche · KU Leuven73 papers (2013–2020)Ann Gils · KU Leuven29 papers (2014–2019)Paul Rutgeerts · KU Leuven28 papers (2013–2020)Bram Verstockt · Imelda Hospital22 papers (2015–2023)Gert De Hertogh · Spaarne Gasthuis21 papers (2013–2021)Vera Ballet · KU Leuven16 papers (2013–2020)Niels Vande Casteele · Medical Research Council16 papers (2014–2019)Isabelle Cleynen · KU Leuven16 papers (2014–2021)Ingrid Arijs · Hasselt University15 papers (2013–2019)Kathleen Machiels · KU Leuven13 papers (2013–2023)Thomas Billiet · KU Leuven12 papers (2013–2017)Erwin Dreesen · American Pharmacists Association12 papers (2016–2023)Albert Wolthuis · Universitair Ziekenhuis Leuven11 papers (2014–2020)Magali de Bruyn · KU Leuven11 papers (2013–2018)Geert D’Haens · Vrije Universiteit Amsterdam11 papers (2013–2025)João Sabino · Madigan Army Medical Center11 papers (2013–2024)Maja Noman · KU Leuven11 papers (2014–2019)Silvio Danese · Io Therapeutics (United States)10 papers (2013–2025)Christine Breynaert · KU Leuven9 papers (2013–2020)